Royalty Pharma Announces Dividend Increase
Rhea-AI Summary
Royalty Pharma (Nasdaq: RPRX) announced a first-quarter 2026 dividend of $0.235 per Class A ordinary share, representing a 6.8% increase versus the prior quarter. The dividend will be paid on March 10, 2026 to shareholders of record at the close of business on February 20, 2026.
Positive
- Dividend increased 6.8% over prior quarter
- Payment date set for March 10, 2026
- Clear record date of February 20, 2026 for eligibility
Negative
- None.
News Market Reaction
On the day this news was published, RPRX declined 0.22%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
NEW YORK, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that its board of directors has declared a dividend for the first quarter of 2026 of
The dividend will be paid on March 10, 2026 to shareholders of record at the close of business on February 20, 2026.
About Royalty Pharma
Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly – directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma’s current portfolio includes royalties on more than 35 commercial products, including Vertex’s Trikafta and Alyftrek, Johnson & Johnson’s Tremfya, GSK’s Trelegy, Roche’s Evrysdi, Servier’s Voranigo, Biogen’s Tysabri and Spinraza, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, Pfizer’s Nurtec ODT, and Gilead’s Trodelvy, among others, and 19 development-stage product candidates. For more information, visit www.royaltypharma.com.
Royalty Pharma Investor Relations and Communications
+1 (212) 883-6637
ir@royaltypharma.com
FAQ
What dividend did Royalty Pharma (RPRX) declare for Q1 2026?
When will Royalty Pharma (RPRX) pay the Q1 2026 dividend?
What is the record date to receive Royalty Pharma's Q1 2026 dividend (RPRX)?
How much did Royalty Pharma (RPRX) increase its quarterly dividend compared to the prior quarter?
Does the Q1 2026 dividend declaration from Royalty Pharma (RPRX) change the share class eligibility?
